PXS
vs
S
S&P/ASX 300
PXS
Over the past 12 months, PXS has underperformed S&P/ASX 300, delivering a return of 0% compared to the S&P/ASX 300's +5% growth.
Stocks Performance
PXS vs S&P/ASX 300
Performance Gap
PXS vs S&P/ASX 300
Performance By Year
PXS vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Pharmaxis Ltd
Glance View
Pharmaxis Ltd. is a pharmaceutical research company, which engages in the development and commercialization of therapeutic products for chronic respiratory disorders, autoimmune diseases, and improved lung function test. The company is headquartered in Frenchs Forest, New South Wales. The company went IPO on 2003-11-10. The firm has two approved respiratory products, Bronchitol and Aridol. The Bronchitol is used for the treatment of cystic fibrosis to help patient’s clear mucus from their lungs. Aridol is a lung function test designed to help doctors diagnose and manage asthma by detecting active airway inflammation through measuring airway hyper-responsiveness. The firm's development pipeline assets include a topical pan-Lysyl Oxidase (LOX) inhibitor in development for scar revision, keloid scarring and scarring from burn wounds; a series of Lysyl Oxidase Like 2 (LOXL2) inhibitors targeting fibrotic diseases of the kidney, lung, liver, and heart; and an anti-inflammatory dual Semicarbazide-Sensitive Amine Oxidase (SSAO)/ Monoamine oxidase B (MAOB) inhibitor targeting Duchenne Muscular Dystrophy.
